Is There Such Thing as Work-Life Balance in Pharmacy?
Pharmacy Times
AUGUST 1, 2022
Many companies overlook the power that workplace culture can have on employee wellness and instead, focus relentlessly on financial metrics.
Mon.Aug 01, 2022
145 
Moderna signs contract to supply Covid-19 booster vaccines to the US
Pharmaceutical Technology
AUGUST 1, 2022
Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates. A bivalent booster candidate, the mRNA-1273.222 vaccine comprises Spikevax along with the Omicron BA.4/5 strain messenger RNA (mRNA).
Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Heavy Alcoholism, ALDH2 rs671 Polymorphism Associated with Higher Risk of Hepatocellular Carcinoma, Mortality
Pharmacy Times
AUGUST 1, 2022
Heavy alcohol intake and ALDH2 rs671 polymorphism are among many risk factors associated with increased risk of hepatocellular carcinoma and mortality in patients with hepatitis B virus-related cirrhosis.
Bristol Myers Squibb aims to improve disability diversity in clinical trials
European Pharmaceutical Review
AUGUST 1, 2022
Dubbed Disability Diversity in Clinical Trials (DDiCT), the initiative aims to provide recommendations on how to improve access, engagement, speed of enrolment and participation of people with disabilities in clinical trials. The goal is to “ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies,” a statement said.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
COVID-19 Pandemic Dramatically Increased Childcare Stress Among Health Care Workers
Pharmacy Times
AUGUST 1, 2022
Researchers found high levels of childcare stress among female and racial minority health care workers, supporting new programs and wellbeing initiatives.
Sarepta says early filing for DMD gene therapy is back on
pharmaphorum
AUGUST 1, 2022
Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to making it available in sometime around the middle of 2023. The US biotech – which already has three antisense drugs for DMD on the market – had said earlier it was planning to delay the application into 2023, so the new announcement marks an acceleration of its plans.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
AbbVie reports 4.5% rise in Q2 2022 net revenues
Pharmaceutical Technology
AUGUST 1, 2022
AbbVie has reported net revenues of $14.6bn for the second quarter (Q2) of 2022 as against $14bn in the year-ago quarter, indicating a 4.5% rise on a GAAP basis. Net revenue surged by 6.1% on an operational basis during the quarter. The GAAP diluted earnings per share (EPS) for the quarter ended 30 June grew by 21.4% to 0.51 from $0.42 in Q2 2021. An 11.2% surge in adjusted diluted EPS of $3.37 was reported in Q2 this year against $3.03 in the prior-year quarter.
The Role of Behavioral Economics in Smoking Cessation
Pharmacy Times
AUGUST 1, 2022
Behavioral economics is a tool that can influence patient behaviors using concepts such as choice architecture, nudges, and loss aversion.
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. The company will jointly design and analyse messenger ribonucleic acid (mRNA) Covid-19 vaccines in partnership with the NIH unit National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC).
FDA Approves Rebinyn for Routine Prophylaxis to Prevent Bleeding in Patients with Hemophilia B
Pharmacy Times
AUGUST 1, 2022
Expanded indication for Rebinyn could allow patients with hemophilia B to participate in physical and social activities.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Big Data Steering Group to enhance data quality and discoverability under new workplan
European Pharmaceutical Review
AUGUST 1, 2022
The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products. “Using novel technologies and the evidence generated from big data will benefit public health by accelerating medicine development, improving treatment outcomes an
A glimpse inside Bristol Myers Squibb’s integration with Celgene
PharmaVoice
AUGUST 1, 2022
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
Governments and pharma relationships and implications for antimicrobial resistance
Pharmaceutical Technology
AUGUST 1, 2022
Before the Covid-19 pandemic, government-led investment and engagement in life sciences was relatively restricted worldwide, with the industry mostly funded via private investment. The pandemic forced governments to acknowledge that this status quo had to change. Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities.
ViiV agrees to expand access to long-acting HIV PrEP
European Pharmaceutical Review
AUGUST 1, 2022
ViiV Healthcare and the Medicines Patent Pool (MPP) have signed a new voluntary licensing agreement to increase access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) in least developed, low-income, lower middle-income and Sub-Saharan African countries. Through this agreement, selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP in 90 countries, subject to required regulatory approvals be
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
BMS’ plan to move Opdivo into adjuvant RCC gets knocked back
pharmaphorum
AUGUST 1, 2022
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most common form of kidney cancer. The disappointing outcome from the CheckMate -914 trial undermines BMS’ hopes of moving PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) treatment into earlier-stage cancers.
GCP update: advice on what to expect and how to prepare
Outsourcing Pharma
AUGUST 1, 2022
With updates to the Guideline for Good Clinical Practice Advancements on the horizon, an industry expert offers some perspective on what might be ahead.
Philips on designing innovation and cultivating partnerships – part two
pharmaphorum
AUGUST 1, 2022
This article follows part one of our two-part series, where we discussed how Philips designs innovation and digital health solutions for areas of India’s healthcare system where options are sparse. . Ties Kroezen, venture leader of Community Life Centers and business development manager for Philips Africa, tells us about the challenges present within the African healthcare system, solutions the company developed to help patients and providers connect, and how pharma can assist with deliver
How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond
PharmaVoice
AUGUST 1, 2022
WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.
Modular Content: a Q&A with Mubasher Hassan, Global Head of Content Management, Grünenthal
PharmExec
AUGUST 1, 2022
A modular content strategy enables better processes, better governance, and better digital asset management.
Rosuvastatin Linked to Signs of Kidney Damage
Pharmacy Times
AUGUST 1, 2022
Compared to atorvastatin, rosuvastatin was associated with higher risks of blood in the urine and kidney failure that requires replacement therapy.
Curavit, Swing team up on fibromyalgia therapeutic trial
Outsourcing Pharma
AUGUST 1, 2022
The CRO and DTx specialist are joining forces to conduct a hybrid clinical trial of a potential digital therapeutic that is aimed at treating fibromyalgia.
Study: Metronidazole Desensitization Effectively Treats Patients with Hypersensitivity Reactions
Pharmacy Times
AUGUST 1, 2022
Patients with past medical histories of immunoglobulin E-mediated hypersensitivity reactions to metronidazole and other antimicrobial agents may receive safe and effective treatment using desensitization protocols.
A Message From Alex August 2022
Oswald's
AUGUST 1, 2022
Once again, it’s what we all seem to say at the beginning of every month—it’s August already!? July flew by here at the pharmacy. Early in the month, I traveled to Washington D.C. for an annual independent pharmacy trade show. The first time it’s been held in person since 2019. No surprise there! The focus… The post A Message From Alex August 2022 appeared first on Oswald's Pharmacy.
Daily Medication Pearl: Phentermine and Topiramate ER (Qsymia)
Pharmacy Times
AUGUST 1, 2022
Phentermine and Topiramate ER (Qsymia) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.
Data analytics hiring levels in the pharmaceutical industry dropped in July 2022
Pharmaceutical Technology
AUGUST 1, 2022
The proportion of pharmaceutical companies hiring for data analytics related positions dropped in July 2022 compared with the equivalent month last year, with 64.8% of the companies included in our analysis recruiting for at least one such position. This latest figure was lower than the 68.8% of companies who were hiring for data analytics related jobs a year ago and a decrease compared to the figure of 69.7% in June 2022.
Oncology Overview: Investigational Autologous TIL Immunotherapy LN-145 for Cervical Cancer
Pharmacy Times
AUGUST 1, 2022
Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Ipsen makes TCR play, grabbing two I-O therapies from Marengo
pharmaphorum
AUGUST 1, 2022
Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 million upfront for rights to early-stage candidates developed by US biotech Marengo Therapeutics. The French pharma group has also promised around $1.6 billion in back-end payments under the terms of the deal, which focuses on a pair of preclinical TCR therapies arising out of Marengo’s elective T Cell Activation Repertoire (STAR) platform.
Ustekinumab Approved to Treat Pediatric Patients With Active Psoriatic Arthritis
Pharmacy Times
AUGUST 1, 2022
Ustekinumab is the first and only biologic that targets both cytokines interleukin (IL)-12 and IL-23.
First monkeypox deaths outside Africa recorded
pharmaphorum
AUGUST 1, 2022
Monkeypox has claimed the first lives outside Africa – one in Brazil and another two in Spain – although the World Health organization (WHO) has said the outbreak remains “containable.” More than 18,000 cases of monkeypox from 78 countries have been reported to the WHO, said WHO director general Tedros Adhanom Ghebreyesus last week, with more than 70% of cases identified in Europe and 25% in the Americas.
Novasep-PharmaZell commits nearly$7.5m to boosting API capacity
Outsourcing Pharma
AUGUST 1, 2022
The contract development and manufacturing organization plans to invest â7.3m to expand and upgrade API production capacity at its Mourenx, France facility.
The Future of Treating AML
Pharmacy Times
AUGUST 1, 2022
The panel concludes with their thoughts on the future of the AML treatment landscape.
Q&A With David Jimenez, President of Janssen Immunology
PharmExec
AUGUST 1, 2022
Jimenez discusses bringing care to diverse and underserved communities.
Daily OTC Pearl: Men’s Bladder Control
Pharmacy Times
AUGUST 1, 2022
Men’s Bladder Control supplements promote bladder and prostate health.
FDA Confirms Ongoing Reliance on Remote Inspection Methods
PharmExec
AUGUST 1, 2022
Citing strong reporting results, hybrid model to continue supplementing on-site inspections.
Let's personalize your content